

1 Article

2 Chemical Vapour Deposition Graphene Field-Effect 3 Transistors for Detection of Human Chorionic 4 Gonadotropin Cancer Risk Biomarker

5 Carrie Haslam¹, Samar Damiati², Toby Whitley¹, Paul Davey¹, Emmanuel Ifeakor¹ and Shakil A.
6 Awan^{1,*}

7 ¹ School of Computing, Electronics and Mathematics, Faculty of Science and Engineering, University of
8 Plymouth, PL4 8AA, UK;

9 ² Department of Biochemistry, Faculty of Science, King Abdulaziz University (KAU), Jeddah, Saudi Arabia;

10 * Correspondence: shakil.awan@plymouth.ac.uk; Tel.: +44(0)1752 586 325

11 **Abstract:** We report on the development of chemical vapour deposition (CVD) based graphene
12 field effect transistor (GFET) immunosensors for the sensitive detection of Human Chorionic
13 Gonadotropin (hCG), a glycoprotein risk biomarker of certain cancers. The GFET sensors were
14 fabricated on Si/SiO₂ substrate using photolithography with evaporated chromium and sputtered
15 gold contacts. GFET channels were functionalized with a linker molecule to immobile anti-hCG
16 antibody on the surface of graphene. Binding reaction of the antibody with varying concentration
17 levels of hCG antigen demonstrated the limit of detection of the GFET sensors was ~0.1 pg/mL
18 using four-probe electrical measurements. We also show annealing can significantly improve the
19 carrier transport properties of GFETs and shift the Dirac point (Fermi level) with reduced p-doping
20 in back-gated measurements. The developed GFET biosensors are generic and could find
21 applications in a broad range of medical diagnostics in addition to cancer, such as
22 neurodegenerative (Alzheimer's, Parkinson's and Lewy body) and cardiovascular disorders.
23

24 **Keywords:** graphene; electrochemical biosensors; cancer; diagnosis; electrical detection;
25 alzheimer's disease; dementia; neurodegenerative disorders; cardiovascular; blood biomarkers;
26 antibodies; proteins
27

28 1. Introduction

29 Since the discovery and isolation of graphene from graphite in 2004, the two-dimensional
30 material has shown potential to revolutionise many technological areas owing to its remarkable
31 electrical, optical, mechanical and thermal properties [1-3]. Graphene is a mono-atomic, planar
32 network of sp²-bonded carbon atoms arranged in a honeycomb lattice. In particular, its chemical
33 stability, low electrical noise, significant surface-to-volume ratio, biocompatibility and field-effect
34 make graphene potentially an ideal platform for a variety of biosensing applications [4]. The
35 extraordinary surface-to-volume ratio of graphene facilitates a high density of disease specific
36 biomarkers to be chemically functionalised onto its surface via covalent or non-covalent
37 immobilisation techniques. A key benefit of the latter is that the electrical transport properties of
38 graphene are not degraded as the mobility and carrier properties are maintained. This can enhance
39 the sensitivity of the biosensor and thereby improve its limit of detection (LoD). Currently, a number
40 of biosensor techniques are being explored to detect the presence of a given biomarker, such as
41 electrical, optical, resonant, acoustical, quartz crystal microbalance and surface plasmon resonance

42 (SPR) [5]. Whilst each technique has its advantages and disadvantages, the electrical technique we
43 are exploring offers some key benefits that make it a prime candidate for eventual point-of-care
44 (PoC) applications in the detection of specific cancer biomarkers and early diagnosis. These include,
45 label-free detection, high sensitivity, multiplexing, low-cost and integration with a range of existing
46 electronic systems. In contrast with our field-effect transistor (FET) biosensors, there are also other
47 electrical techniques, such as cyclic voltammetry (CV), impedimetry and amperometry functioning
48 to detect a variation in resistance and/or capacitance, that may be comparable to the FET approach in
49 terms of sensitivity. The developed FETs will be generic sensors and are therefore expected to have
50 numerous other applications ranging from neurodegenerative disorders (ND), such as Alzheimer's
51 [6] and other dementias, and cardiovascular to infectious diseases and environmental monitoring.

52 Here we report on the chemical vapour deposition (CVD) graphene field-effect transistor
53 (GFET) biosensors aimed at detecting the presence of Human Chorionic Gonadotropin (hCG)
54 protein biomarkers in samples from patients at different stages of disease progression. The
55 proof-of-concept GFETs were functionalized with monoclonal anti-hCG antibodies for the detection
56 of hCG protein biomarkers, label-free. hCG is a glycoprotein hormone (37-kDa) and its concentration
57 level serves as a clinical marker associated with testicular, pancreatic and prostate cancer [7-9], as
58 well as pregnancy. As with many diseases, early cancer recognition and diagnosis can be critical for
59 treatment and management to be effective, as well as enabling optimum health care provision and
60 potentially opening novel routes to be investigated to prevent the development of the disease
61 [10-12]. There is therefore an urgent need to develop diagnostic sensors and analytical tools for the
62 accurate identification and early diagnosis of cancer. hCG is composed of two subunits α and β ,
63 which are non-covalently linked by hydrophobic and ionic interactions. The α subunit is known to
64 be common and the β subunit is unique to hCG, conferring biological activity to the hormone. The
65 length of the β subunit is composed of 145 amino acids [13-17]. As a pregnancy biomarker hCG is
66 usually secreted by the trophoblast cells of the placenta peaks at ~ 10 weeks into the human gestation
67 period. The chief function of hCG is considered to maintain the corpus luteum and promote the
68 production of progesterone during pregnancy by the ovarian granulosa cells, whilst endorsing foetal
69 growth [18-22]. A typical, commercial biosensor that is designed to detect hCG and establish
70 pregnancy exhibits sensitively down to a nano-molar range [23]. It has been previously estimated
71 that 95% of pregnancies can be detected at a sensitivity of 12.4 mIU/mL at the time of an expected
72 menstrual period [24-25]. Our GFET biosensors detailed here exhibit a significantly lower limit of
73 detection of 0.1 pg/mL (determined using a 4-probe electrical technique) compared to a commercial
74 biosensor designed specifically for hCG detection. There are number of other studies that have
75 investigated hCG biomarker to analyse the necessary LoD of their sensors, e.g. Heideman *et al.* [26],
76 where they developed a Mach-Zehnder interferometer (MZI) immunosensor, based on a silicon
77 substrate with a detection limit of 50pM [[26,27]. In respect to hCG detection via graphene, Teixeira
78 *et al.* [15] applied chemically-modified multi-layer epitaxial graphene to serve as the sense electrode
79 (functionalized with APTES). The device displayed a LoD of 0.62 ng/mL [15]. In addition, Teixeira *et al*
80 *al* produced an immunosensor based on screen-printed electrodes (SPEs), with graphene functioning
81 as the working electrode to detect hCG. The LoD was determined to be 0.286 pg/mL [28]. To the best
82 of our knowledge, there has not yet been a CVD graphene biosensor reported that has been able to detect
83 hCG concentration at the ~0.1 pg/mL level. The developed GFET biosensors will also need to be
84 validated against the gold standard in the field, that of immunoassay enzyme-linked

85 immunosorbent assay (ELISA). In addition, since performing ELISA tests can be time consuming,
86 requires high level of operator expertise and complex equipment, making it expensive, we envisage
87 that GFET biosensors could present a potential low-cost, fast, accurate and reliable alternative
88 technology platform.

89 2. Materials and Methods

90 Monolayer Graphene on a SiO₂/Si wafer was purchased from Graphenea (Spain). The required
91 chemicals applied for GFET fabrication were photoresist (PR), lift-off resist (LoR), Microposit
92 developer and Microposit remover, all purchased from A-Gas Electronic Materials (Warwickshire,
93 UK).

94 The hCG antigen and complementary anti-hCG monoclonal antibody were purchased from
95 Abcam (UK). The stock were stored at -20 °C. Linker molecule 1-pyrenebutanoic acid succinimidyl
96 ester (Pyr-NHS) and bovine serum albumin (BSA) blocking solution were purchased from Sigma
97 Aldrich (Dorset, UK). Phosphate-Buffered Saline (PBS) tablets were purchased from Sigma Aldrich
98 (Germany).

99 Electrical characterisation and analysis were implemented under ambient conditions via a
100 Keysight B1500A semiconductor device parameter analyser, in conjunction with a Cascade
101 Microtech MPS150 probe station (Thiendorf, Germany). Current-voltage measurements (I_D - V_D and
102 I_D - V_G) were executed as a function of gate voltage (V_G) from - 100 V to + 100 V. The I_D - V_D curves were
103 acquired from - 100 mV to + 100 mV. The I_D - V_D and I_D - V_G curves were measured for each separate
104 functionalisation stage.

105 Graphene characterisation was performed using an XPLOA Raman spectroscopy system
106 (HORIBA, UK). The XPLOA system operated at a wavelength of 532 nm, with ~ 4 mW of incident
107 power. The XPLOA Raman system was combined with an OLYMPUS BX41 microscope (Olympus,
108 Japan).

109 To define and develop the necessary graphene channels and metallic contacts of Chromium
110 (Cr) and Gold (Au), the Mask aligner J500/VIS (OAI optical associates Inc) was deployed. A
111 conventional fan oven (WTB binder, Germany) was employed to perform necessary annealing
112 processes, as well as for pre- and post-baking stages during the photolithography processes. The
113 Hotplate SH8 (STUART SCIENTIFIC) and Ultrasonic Cleaner (CBEST, US) were used for pre- and
114 post-baking procedures and PR removal, respectively. An Argon (Ar) plasma etching technique
115 was used for graphene channel formation by means of a three target, 6-inch sputtering machine
116 (Nordiko Limited, UK). To aid in the formation of robust, metallic electrodes, an Edwards Thermal
117 Evaporator was deployed for the evaporation of Cr.

118

119 2.1. Fabrication of CVD Graphene FETs

120 The GFETs were fabricated using high quality CVD graphene to form transducer channels on
121 Si/SiO₂ substrate. A conventional photolithographic patterning and metal lift-off technique was used
122 to form the necessary graphene channels, as well as the source, drain and voltage sense electrodes.
123 The fabrication process involved spin-coating the CVD graphene samples with Lift-off Resist (LOR)
124 at 3000 rpm for a few seconds. The samples were then placed in a fan oven for pre-baking. The
125 purpose of the pre-bake was to densify the LOR to assist with the formation of clear, graphene
126 channels. Subsequently, the samples were dried at an ambient temperature. Next, the samples were


127 spin-coated with a layer of positive Photoresist (PR). Immediately after PR deposition, the samples
128 were post-baked on a hotplate. The hotplate solidifies the PR and removes any solvents remaining
129 on the samples. This process generated ~ 500 nm of PR film on the surface of graphene. Successively,
130 the coated samples were then positioned in a mask aligner and exposed to ultra-violet (UV)
131 radiation for lithographic patterning of graphene channels. The UV exposed samples were also
132 submerged in a chemical developer before being placed in a vacuum chamber to dry. Alternatively,
133 the samples can be left to dry at ambient temperature, outside of the vacuum chamber. An
134 additional post-baking stage was applied to the samples following the drying and placed on a
135 hotplate under an intermittent deep ultraviolet source (DUV). This exposure to DUV can reduce the
136 quantity of PR/PMMA residue on the substrate surface prior to plasma etching, whilst reducing
137 contact resistance.

138 The chemically developed and dried samples were transferred into a sputtering machine and
139 exposed to Ar plasma etching for few minutes. Throughout the process, the inert Ar gas functions
140 as the gaseous etchant and removes the exposed regions of graphene, whilst leaving behind the
141 shaped graphene channels (previously coated and protected with PR). Graphene shaping is
142 effectively complete after an etching time of a few minutes at high power. The sputtering machine
143 was also used to sputter and form the associated metallic electrodes, 30 nm of Au. Following
144 successful shaping, the samples were transferred to a chemical remover to dissolve the LoR and PR
145 remaining on the substrate to expose the graphene channels. The samples were immersed in the
146 chemical remover, whilst located in an ultrasonic bath for ~2 hour at ~60°C. The samples were
147 subsequently rinsed and bathed in de-ionised water and transferred into a vacuum chamber to dry
148 for few hours.

149 For the final stage of GFET fabrication, metallic Cr and Au electrodes were formed on the
150 graphene channels. The samples were post-baked in a fan oven, instead of being irradiated with
151 DUV. This post-baking stage is necessary to remove the solvents located within the PR and
152 eliminate any additional water. Following photolithography, thermal evaporation of Cr was
153 performed using an Edwards Thermal Evaporator for a few seconds. The Cr functions as an
154 adhesive layer between graphene and the Au metallic contacts. The Cr target material was heated
155 to ~2000°C and evaporated within a high vacuum. The heated coil of Cr is applied to form a thin
156 film of ~5 nm on the surface of the graphene samples. The metallic contacts are fully formed after
157 sputtering 30 nm of Au on the Cr film. After the Au sputtering process, the initial chemical remover
158 step is repeated and the final samples are dried in a vacuum chamber for a few hours, prior to
159 electrical characterisation.

160 For this study a number of CVD graphene samples were fabricated. Each sample consisted of
161 fifteen GFET devices (with an area of ~1 cm²) in total, i.e. five GFET devices consisted of five
162 asymmetric Cr/Au voltage sense electrodes with an associated graphene channel length of 720 μm,
163 whereas the remaining ten GFET devices consisted of six symmetric voltage sense electrodes with a
164 channel length of 300 μm, as shown in Fig. 1. The width of all GFET channels was fixed at 80 μm.
165
166
167
168
169
170
171

172
173
174
175
176
177
178



179 **Figure 1:** Graphene FET devices with asymmetric (left) and symmetric (right) voltage sense
180 electrodes. Graphene channels, in the central regions of the FET devices, have a dark blue contrast
181 compared to the Si/SiO₂ substrate.

182 3. Results

183 3.1. Characterisation of CVD Graphene using Raman Spectroscopy

184 Raman spectroscopy was performed on two representative CVD samples to analyse the quality
185 of graphene and to estimate various properties, such as number of layers [29], doping and residues
186 from the fabrication process. Random spot Raman measurements were carried out at the central
187 region of bare samples. The Raman spectra were measured with a 10X objective, under ambient
188 conditions with an incident power of ~ 4 mW and a wavelength of 532 nm. Figure 2 shows Raman
189 spectra from the two samples with an intensity ratio of the 2D peak to G peak of $I(2D)/I(G) \sim 2$ and
190 one sample shows a significant D peak, whereas it is absent in the other. The intensity ratio
191 $I(2D)/I(G)$, position and full width half maximum (FWHM) of the G and 2D peaks confirm presence
192 of monolayer graphene. The presence and intensity of the D peak in one of the samples also indicates
193 that the graphene in that sample contains defects. Raman mapping of a few regions of the graphene
194 wafer (before it was diced into 1cm² samples) confirmed majority of the regions consisted of
195 mono-layer graphene.

196 3.2. Electrical Characterisation of GFETs

197 The GFETs were characterized using 2-probe, 4-probe and back-gated measurements under ambient
198 conditions. The bare GFETs (i.e. without any biomolecule functionalization) were first measured to
199 extract the I_D - V_D characteristics of the fifteen devices on each 1 cm² sample. A comparison between
200 2-probe, 4-probe and back-gated data enabled us to extract the contact resistance, mobility and
201 sheet resistance of the graphene channels within the GFET devices. A typical 4-probe I_D - V_D and
202 I_D - V_G measurements from a GFET sensor using a Keysight parameter analyser interfaced to a
203 Cascade probe station is shown in Fig. 3. The I_D - V_D data shows approximate linear response over
204 the ± 60 mV range and a slight non-linearity beyond this range probably due to adsorbed water
205 molecules on the surface of the graphene channel and charge traps in the Si/SiO₂ substrate. This is
206 further confirmed from the I_D - V_G data which shows a characteristic hysteretic behavior due to the
207 presence of polar molecules on the surface of graphene and charge traps. The Dirac point is found
208 to vary from 50 V to 80 V depending on the voltage sweep and its positive magnitude indicates the
209 graphene channel is p-doped. The 4-probe resistance of the graphene channel is found to be ~700 Ω ,
210 whereas the mobility is approximately 1200 cm²/Vs.

211






Figure 2: Raman Spectra of quality and defected CVD graphene before being deployed as the transducer element in a GFET biosensor. The defected sample (blue) shows a prominent D-band.

We have also explored the effect of annealing on our devices in order to improve the overall performance of the bare GFET sensors. Figure 4 displays the results from one device before and after annealing. Before annealing the device showed relatively low conduction level and its Dirac point was in excess of 40 V. However, after annealing the sample, the Dirac point could now be discerned and shifted to approximately 23 V (with p-type doping). This is likely due to desorption of oxygen and water molecules from the surface of graphene [30-32]. In pristine graphene, the Dirac point would ideally be located at zero gate voltage. A Dirac point situated relatively far from the zero point indicates unintentional doping, which could be due to the fabrication process. The location of the Dirac point is dependent on the difference between the work function of the gate, metallic contacts, and the graphene channel, as well as doping and the presence of biomolecules adsorbed on the surface [33]. From a knowledge of the Dirac point and shape of the I_D - V_G curve near its vicinity, a number of properties of the channel can be estimated, such as mobility, doping, defects etc.



268
269 **Figure 3:** I_D - V_G and the corresponding I_D - V_D (inset) of a CVD graphene FET sensor. The arrows
270 indicate forward and reverse sweep of the back-gate voltage showing hysteretic behavior.
271




283
284 **Figure 4:** Annealed I_D - V_G curve of a CVD graphene FET and its corresponding
285 I_D - V_G (inset) before annealing.
286

287 3.3. Functionalisation of GFETs

288 To facilitate antibody (Ab) immobilization, we used a linker molecule Pyr-NHS ester. The linker
 289 retains a succinimidyl ester group, which interacts with the amino groups on the anti-hCG Ab
 290 surface to generate a stable, amide bond. In addition, the Pyr-NHS has an aromatic pyrenyl group,
 291 which can strongly interact with the graphene surface, via a non-covalent π - π stacking.
 292 Non-covalent binding is dependent on physical adsorption of the biomolecule, using hydrophobic,
 293 hydrophilic, electrostatic and van der Waals interactions. Thus, Pyr-NHS ester causes the pyrene
 294 group at one end of the linker to strongly bind to the graphene surface via π - π interactions and the
 295 succinimidyl ester group will covalently react with the amino group (NH₂) of the Ab without
 296 requiring a high pH [34]. The non-covalent attachment of Pyr-NHS ester with graphene does not
 297 disrupt the electrical properties of graphene, whereas covalent bonding can lead to scattering and
 298 the introduction of impurities in the graphene sp² lattice. This type of immobilisation typically leads
 299 to a self-assembled monolayer (SAM) of molecules on the surface of graphene, although the Abs
 300 may remain randomly orientated.

301 The GFET devices were biologically modified and converted into biosensors via the drop
 302 casting of biomolecules. Initially, Pyr-NHS ester linker molecules were applied to cover the surface
 303 of the graphene channels at a concentration of 2 mM. The samples were incubated at low
 304 temperature for a few hours before rinsing with PBS and drying at ambient temperature. Once the
 305 samples were dry, electrical characterisation was performed. Following attachment of Pyr-NHS
 306 ester and electrical characterisation, anti-hCG Ab was applied to the samples and again incubated
 307 before rinsing with PBS and drying at ambient temperature. The same process was repeated for
 308 BSA deposition. Finally, hCG antigen was applied to the samples at a concentration ranging from
 309 0.1 pg/mL to 1 ng/mL and characterised using 4-probe electrical measurements. Samples were then
 310 incubated at ambient conditions for 1 hour, prior to a PBS rinse. Figure 5 illustrates the steps
 311 involved within the functionalisation process.

312



313

314

315 **Figure 5:** GFET functionalisation and antigen detection stages for (A) bare graphene (B)
 316 non-covalent attachment of Pyr-NHS ester linkers with graphene (C) anti-hCG antibody (light blue)
 317 attachment to the linkers (D) BSA blocking (dark blue) and (E) hCG antigen (red) binding with the
 antibody. Each stage is characterised using 4-probe electrical measurements of I_D - V_D and I_D - V_G .

318 3.4. Atomic Force Microscopy of Functionalised GFETs

319 Further characterisation of the functionalised GFETs was performed using Atomic Force
320 Microscopy (AFM, Pacific Nanotechnology and probe tips from Nano World). Multiple AFM images
321 were generated in respect to the various necessary functionalisation steps. The difference in height
322 and morphology at hCG functionalisation stage is displayed in Figure 6. The AFM image illustrates
323 the successful immobilisation of Pyr-NHS linker, Ab, BSA and the corresponding hCG antigen
324 molecules on the surface of the graphene FETs. The hCG antigen is measured to be ~7-10 nm in
325 height.

326

327


328

329

330

331

332



333 **Figure 6:** AFM image of bare graphene on Si/SiO₂ (left) and immobilised with Pyr-NHS linker,
334 Ab, BSA and the corresponding hCG antigen (right).

335

336 3.5. Scanning Electron Microscopy of Functionalised GFETs

337 SEM Image (using a JOEL JSM-7001F) shows a GFET device with 10 pg/mL of hCG antigen on
338 the surface of graphene, including immobilisation of Pyr-NHS ester linker, Ab and BSA. The image

339

340

341

342

343

344

345

346

347

348

349

350

351


352

353

354

355

356



357 **Figure 7:** SEM image displaying bare graphene immobilised with Pyr-NHS linker, Ab, BSA
358 and the corresponding hCG antigen. Scale bar is 1 µm.

359 (taken at 25,000 times magnification) shows hCG appearance to be foam like with relatively large
 360 voids over the $5\mu\text{m} \times 5\mu\text{m}$ region. The hCG appears also not to be uniformly distributed, indicating
 361 further optimisation may be needed to achieve a uniform distribution of the antigen on the surface
 362 of graphene to enable consistent and repeatable response of the GFET biosensors.

363 3.6. Detection of hCG concentration

364 The fabricated GFET sensors were characterised using 4-probe electrical measurements at each
 365 stage of the functionalisation and binding interactions of the anti-hCG antibody with hCG antigen at
 366 varying concentration levels of the latter. All measurements were performed in ambient conditions.
 367 Figure 8 shows the response curves of two GFET biosensors when exposed to 1 pg/mL and 1 ng/mL
 368 hCG antigen. The corresponding changes in resistance at each stage and concentration levels are
 369 shown in Table 1. A striking feature of the results shown in Figure 8 and Table 1 is that whilst the
 370 change in resistance coefficient ΔR for 1 pg/mL is positive for all stages of the functionalisation, this
 371 is not the case for the 1 ng/mL concentration level. In this case, the coefficient is negative until
 372 antibody binding stage but then becomes positive. In addition, despite 3 orders-of-magnitude
 373 difference between the 1 pg/mL and 1 ng/mL concentration levels the change in resistance coefficient
 374 is $\sim 114.1\%$ and $\sim 305\%$, respectively. In contrast, we measured $\Delta R \sim 135.9\%$ for 10 pg/mL and a LoD of
 375 the sensors to be ~ 0.1 pg/mL, as shown in Fig. 9. The response of the GFET sensors to hCG antigen
 376 concentration is found to be linear over the 1 pg/mL to 1 ng/mL range, as shown in Fig. 9. The
 377 least-square linear fit to the measured GFET 4-probe resistance change shows reasonably good fit
 378 with $R^2 \sim 0.95$. The corresponding sensitivity of the GFET biosensors is found to be $\sim (66.7 \pm 15)\%$ /
 379 decade of hCG concentration over the 1 pg/mL to 1 ng/mL range. This represents a significant
 380 sensitivity level for hCG antigen detection. However, it is worth highlighting that our GFET
 381 biosensors have not yet been optimised for numerous parameters (mobility etc.) to achieve even
 382 higher sensitivity levels and lower detection limits. These aspects are currently being explored and
 383 will be reported on in subsequent future publications.

384 The data in Table 1 for the measured 4-probe resistance of the GFET sensors at 1 pg/mL and
 385 1 ng/mL concentration levels also includes the change in resistance coefficient ΔR . This is calculated
 386 relative to the two nearest stages, i.e. bare graphene to linker, linker to Ab, etc. Thus, sensitivity of
 387 the sensors can be estimated from ΔR for hCG (or change in resistance from BSA to the hCG
 388 analyte).

389

390

391

392

393

394


395

396

397 **Figure 8:** Characteristic I_D - V_D curves from the GFET sensors at different stages of biomolecule
 398 exposure for 1pg/mL (left) and 1ng/mL (right) hCG concentration levels.

399

400



401
402
403
404

Table 1. Summary of GFET resistance changes measured at different stages of the functionalisation process with 1pg/mL to 1ng/mL concentration of hCG antigen.

Stage	1pg/mL(Ω)	ΔR (%)	1ng/mL(Ω)	ΔR (%)
Bare	741.8	0	6686.3	0
Linker	2341.9	+215.7	3733.3	-44.2
Ab	2590.7	+10.6	3361.7	-11.1
BSA	3021.0	+16.6	4065.4	+20.9
hCG	6467.5	+114.1	16468.5	+305.1

405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422




Figure 9: Measured resistance change coefficient with hCG concentration and a least-squares linear fit to the data from 1 pg/mL to 1 ng/mL range.

423
424
425
426
427
428

4. Discussion

429
430
431
432
433
434
435

The proof of concept CVD graphene FET biosensors have been characterised at all stages of the fabrication process (Raman, AFM, electrical) and functionalisation (Raman, AFM, SEM, electrical) to establish a robust and reproducible process for the development of the sensors. Our data presented in this study has demonstrated that proof-of-concept CVD graphene FETs can sensitively detect hCG antigen with approximately two orders of magnitude lower concentration level compared to commercial sensors. In addition, the GFET sensors can be operated in a resistive or back-gated mode

436 and in the future we aim to compare the sensitivity of these two approaches. However, the data in
437 Figure 8 shows clear characteristic curves for a resistive GFET sensor which we also observed for the
438 10 pg/mL concentration level of the hCG antigen. As shown in Figure 3, back-gated GFET sensor
439 properties can be influenced due to the presence of water molecules on the surface of graphene and
440 charge traps in the supporting substrate (in our case Si/SiO₂) leading to hysteretic effects. Therefore,
441 a robust comparison of the resistive with back-gated GFET sensors will require careful device design
442 and optimisation.

443 Annealing of the GFET biosensors showed remarkable improvements in their electrical
444 performance, in terms of enhanced carrier transport properties and Dirac point shift due to oxygen
445 and water molecules being desorbed from the surface of graphene. Work is currently underway to
446 compare annealed devices with those that have been fabricated in the same batch but not annealed.
447 In addition, all the results reported in this study are based on direct current (DC) 4-probe resistance
448 measurements. We therefore anticipate further improvements in S/N can also be achieved using
449 alternating current (AC) or radio-frequency (RF) detection techniques [35,36].

450

451 5. Conclusions

452 We have demonstrated the use of CVD graphene FETs on Si/SiO₂ substrate as sensitive
453 immunosensors for the proof-of-concept detection of hCG antigen, with a LoD ~0.1 pg/mL.
454 Although characteristic current-voltage response curves of the GFETs have been established, the
455 sign of the resistance change coefficient ΔR has a strong dependence on the concentration level of the
456 antigen. In addition, we have also shown that annealing the GFET sensors can significantly improve
457 their performance and potentially lead to even more sensitive devices. In the near future the GFET
458 biosensors will be explored for the detection of hCG biomarkers in case vs control samples from
459 patients. Furthermore, in the next stage of development of the GFETs we will also investigate
460 optimisation of the quality of CVD graphene, contact resistance and novel AC and RF detection
461 techniques to enhance the sensitivity of the biosensors.

462

463 Acknowledgements

464 We acknowledge funding from the UK's Engineering and Physical Sciences Research Council
465 (EPSRC) under contract number EP/M006301/1 and the University of Plymouth, GD105227. SD
466 would like to thank University of Plymouth, UK, for a guest-researcher position in summer 2017.

467

468 References

- 469 1. Novoselov, K.S., et al., *Electric field effect in atomically thin carbon films*. *Science*, 2004.
470 **306**(5696): p. 666-9.
- 471 2. Geim, A.K., *Graphene: status and prospects*. *Science*, 2009. **324**(5934): p. 1530-4.
- 472 3. Geim, A.K. and P. Kim, *Carbon wonderland*. *Sci Am*, 2008. **298**(4): p. 90-7.
- 473 4. Forsyth, R., A. Devadoss, and O.J. Guy, *Graphene Field Effect Transistors for Biomedical*
474 *Applications: Current Status and Future Prospects*. *Diagnostics (Basel)*, 2017. **7**(3).

- 475 5. Allsop, T., et al., *Real-time kinetic binding studies at attomolar concentrations in solution phase*
476 *using a single-stage opto-biosensing platform based upon infrared surface plasmons*. Opt Express,
477 2017. **25**(1): p. 39-58.
- 478 6. World Alzheimer's Report 2016. Publisher, *Alzheimer's Disease International*, September 2016.
- 479 7. Sánchez, S., et al., *Toward a fast, easy, and versatile immobilization of biomolecules into carbon*
480 *nanotube/polysulfone-based biosensors for the detection of hCG hormone*. Analytical chemistry,
481 2008. **80**(17): p. 6508-6514.
- 482 8. Sinosich, M.J., H. Torode, and D. Saunders, *Diagnosis and management of extrauterine*
483 *pregnancies*. Australian and New Zealand journal of obstetrics and gynaecology, 1993. **33**(3):
484 p. 307-311.
- 485 9. Santandreu, M., S. Alegret, and E. Fabregas, *Determination of β -HCG using amperometric*
486 *immunosensors based on a conducting immunocomposite*. Analytica Chimica Acta, 1999. **396**(2):
487 p. 181-188.
- 488 10. Yang, W., et al., *Carbon nanomaterials in biosensors: should you use nanotubes or graphene?*
489 *Angewandte Chemie International Edition*, 2010. **49**(12): p. 2114-2138.
- 490 11. Chen, A. and S. Chatterjee, *Nanomaterials based electrochemical sensors for biomedical*
491 *applications*. Chemical Society Reviews, 2013. **42**(12): p. 5425-5438.
- 492 12. Pumera, M., *Graphene in biosensing*. Materials today, 2011. **14**(7): p. 308-315.
- 493 13. Pierce, J.G. and T.F. Parsons, *Glycoprotein hormones: structure and function*. Annual review of
494 biochemistry, 1981. **50**(1): p. 465-495.
- 495 14. Stenman, U.-H., et al., *The classification, functions and clinical use of different isoforms of HCG*.
496 *Human reproduction update*, 2006. **12**(6): p. 769-784.
- 497 15. Teixeira, S., et al., *Epitaxial graphene immunosensor for human chorionic gonadotropin*. Sensors
498 and Actuators B: Chemical, 2014. **190**: p. 723-729.
- 499 16. Netto, G.J. and J.I. Epstein, *Chapter 16 - Immunohistology of the Prostate, Bladder, Kidney, and*
500 *Testis A2 - Dabbs, David J*, in *Diagnostic Immunohistochemistry (THIRD EDITION)*. 2011, W.B.
501 Saunders: Philadelphia. p. 593-661.
- 502 17. Cole, L.A., *Biological functions of hCG and hCG-related molecules*. Reproductive Biology and
503 Endocrinology : RB&E, 2010. **8**: p. 102-102.
- 504 18. Bahadır, E.B. and M.K. Sezgintürk, *Applications of electrochemical immunosensors for early*
505 *clinical diagnostics*. Talanta, 2015. **132**: p. 162-174.
- 506 19. Tsampalas, M., et al., *Human chorionic gonadotropin: A hormone with immunological and*
507 *angiogenic properties*. Journal of Reproductive Immunology, 2010. **85**(1): p. 93-98.
- 508 20. Cole, L.A., *hCG, five independent molecules*. Clinica chimica acta, 2012. **413**(1): p. 48-65.
- 509 21. Korevaar, T.I.M., et al., *Reference ranges and determinants of total hCG levels during pregnancy:*
510 *the Generation R Study*. European Journal of Epidemiology, 2015. **30**(9): p. 1057-1066.
- 511 22. Larsen, J., et al., *Human chorionic gonadotropin as a measure of pregnancy duration*. International
512 Journal of Gynecology & Obstetrics, 2013. **123**(3): p. 189-195.
- 513 23. Bahadır, E.B. and M.K. Sezgintürk, *Applications of commercial biosensors in clinical, food,*
514 *environmental, and biothreat/bio warfare analyses*. Analytical Biochemistry, 2015.
515 **478**(Supplement C): p. 107-120.
- 516 24. Cole, L.A., et al., *Accuracy of home pregnancy tests at the time of missed menses*. American journal
517 of obstetrics and gynecology, 2004. **190**(1): p. 100-105.

- 518 25. Gnoth, C. and S. Johnson, *Strips of Hope: Accuracy of Home Pregnancy Tests and New*
519 *Developments*. *Geburtshilfe und Frauenheilkunde*, 2014. **74**(7): p. 661-669.
- 520 26. Heideman, R., R. Kooyman, and J. Greve, *Performance of a highly sensitive optical waveguide*
521 *Mach-Zehnder interferometer immunosensor*. *Sensors and Actuators B: Chemical*, 1993. **10**(3): p.
522 209-217.
- 523 27. Fan, X., et al., *Sensitive optical biosensors for unlabeled targets: A review*. *Analytica Chimica Acta*,
524 2008. **620**(1): p. 8-26.
- 525 28. Teixeira, S., et al., *Label-free human chorionic gonadotropin detection at picogram levels using*
526 *oriented antibodies bound to graphene screen-printed electrodes*. *Journal of Materials Chemistry B*,
527 2014. **2**(13): p. 1852-1865.
- 528 29. Ferrari, A.C., et al., *Raman spectrum of graphene and graphene layers*. *Physical review letters*,
529 2006. **97**(18): p. 187401.
- 530 30. Tien, D.H., et al., *Characterization of Graphene-based FET Fabricated using a Shadow Mask*.
531 *Scientific reports*, 2016. **6**: p. 25050.
- 532 31. Chen, S., et al., *Adsorption/desorption and electrically controlled flipping of ammonia molecules on*
533 *graphene*. *New Journal of Physics*, 2010. **12**(12): p. 125011.
- 534 32. Joshi, P., et al., *Intrinsic doping and gate hysteresis in graphene field effect devices fabricated on SiO₂*
535 *substrates*. *Journal of Physics: Condensed Matter*, 2010. **22**(33): p. 334214.
- 536 33. Chen, F., J. Xia, and N. Tao, *Ionic screening of charged-impurity scattering in graphene*. *Nano*
537 *Letters*, 2009. **9**(4): p. 1621-1625.
- 538 34. Huang, Y., et al., *Graphene-based biosensors for detection of bacteria and their metabolic activities*.
539 *Journal of Materials Chemistry*, 2011. **21**(33): p. 12358-12362.
- 540 35. Awan, S., et al., *Transport conductivity of graphene at RF and microwave frequencies*. *2D*
541 *Materials*, 2016. **3**(1): p. 015010.
- 542 36. Awan, S., et al., *Coaxial electrical circuits for interference-free measurements*. 2011, IET.